about
Management of inflammatory bowel disease in pregnancySafety of TNF-α inhibitors during IBD pregnancy: a systematic reviewReview article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient.The use of anti-TNFα medications for rheumatologic disease in pregnancy.Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding.Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.The management of rheumatic diseases in pregnancySafety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.Behçet's syndrome in pregnancy.Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-makingManagement of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further EducationUse of infliximab in particular clinical settings: management based on current evidence.Management of early aggressive rheumatoid arthritis during pregnancy and lactation.From conception to delivery: managing the pregnant inflammatory bowel disease patient.Treatment of inflammatory bowel disease and pregnancy: a review of the literature.Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.European evidenced-based consensus on reproduction in inflammatory bowel disease.Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients.How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.High-risk pregnancy and the rheumatologist.Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues.Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy.Management of Inflammatory Bowel Disease During Pregnancy.A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy.Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period.Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease.Infliximab for the treatment of ulcerative colitis.Successful treatment with infliximab for Behçet disease during pregnancy.
P2860
Q26865914-D6A6D12E-6648-436B-A2C9-6B6E47E530D3Q27008090-085E1B59-9E53-4E9B-A995-2E943AC6D6E1Q34244877-0362E5DE-7517-4279-8360-4C577CBED28CQ34272138-C27ABDF3-DE1F-4C0B-9FDC-2A698FD4E849Q35892193-A7A061FD-706C-4583-8581-2BF2890DA198Q36819564-27F698C2-D037-4EC3-9364-42B2C41652BDQ37047839-EFED89B8-2977-4B3B-8744-AEEFBFF536AFQ37149381-4B14CE45-1E67-4901-8473-CEB0EA3ACC89Q37186394-F0724C90-1A39-4131-BF9A-40F291CAA929Q37224385-A21A7558-AD4A-498A-8AA3-2278522EDE0DQ37306723-01CDDF51-6895-4FE2-A5AC-9A5F19A206D6Q37506064-681120C1-A1A0-4CF9-BAAC-1BF80BB1BF0EQ37510901-5D3A2403-4243-40EF-A14A-938193BCA94AQ37682503-DA94BC30-F7E4-4E17-B62A-09BE29B8A643Q37780963-B1F8E7FF-7E99-4E66-BED9-C4264E486CCBQ37798387-0BE8D337-E274-4518-80F9-996A644C3B8BQ37814549-71D29877-604A-4F3C-88F9-5BDABA69F95EQ37814564-C695095E-622B-4B0B-9C63-CF2AB52119A7Q38113455-0F6BC660-C7B3-4F97-8F05-1E3DC3AC684EQ38205869-1041CC9A-9265-44E7-8112-A5DCC1F3F79EQ38253145-62ACFD3C-E571-48A6-BD74-42A1CD3AA9AAQ38269243-646036C5-4ACE-45B6-B577-9A7F88C14033Q38283472-7D3DFF9C-1DD9-4BAC-A31E-49A8EA5C1C35Q38464355-7A081867-5675-43FE-B302-EA1BF3C976A6Q38661263-8378B49B-630D-49BE-A052-DCDE4ECA4325Q38805484-FAA84FD7-3F8F-497B-8154-FD28CDAB6F16Q38996685-977049D5-8703-4825-91EE-F12227F5318CQ39029592-CAC48299-795E-48C7-8B1B-766F9CFE66E4Q43132889-763A70BD-A9AF-419B-A3C1-0FCA0DCC2BDAQ45247701-CF012D5C-61CE-4F6B-A91D-897C164A1C38Q45951213-EE93C09E-D6A9-47B5-B556-0BC2E0D89265Q46015179-50C6D5BF-17C2-4E24-A956-8F9B3847CEBBQ47682064-43F47E14-C2C4-4D05-8F6F-86714BAA2A7DQ51041878-45692E8C-C6DC-4E84-8D3B-CD2D240ABD92
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is infliximab safe to use while breastfeeding?
@en
Is infliximab safe to use while breastfeeding?
@nl
type
label
Is infliximab safe to use while breastfeeding?
@en
Is infliximab safe to use while breastfeeding?
@nl
prefLabel
Is infliximab safe to use while breastfeeding?
@en
Is infliximab safe to use while breastfeeding?
@nl
P2860
P356
P1476
Is infliximab safe to use while breastfeeding?
@en
P2093
Hays-L Arnold
Joel-Z Stengel
P2860
P304
P356
10.3748/WJG.14.3085
P407
P577
2008-05-01T00:00:00Z